Monoclonal Caninized Antibody (Mab) Treatment

13 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

770.0%

Death Rate

Active Ingredients

Monoclonal Caninized Antibody (Mab) Treatment

Administration Routes

UnknownSubcutaneous

Species Affected

Dog 13

Most Affected Breeds

Shepherd Dog - Australian 2

Boxer (German Boxer) 1

Spaniel (unspecified) 1

Crossbred Canine/dog 1

Dachshund - Miniature 1

Setter - English 1

Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1

Pit Bull 1

Bulldog - English 1

Poodle - Toy 1

Most Reported Reactions

Vomiting 5

Lethargy (see also Central nervous system depression in Neurological) 3

Hives (see also Skin) 2

Erythema (for urticaria see Immune SOC) 2

Decreased appetite 2

Diarrhoea 2

Behavioural disorder NOS 2

Low platelet count 1

Elevated total bilirubin 1

Leucocytosis NOS 1

Elevated lipase 1

Elevated serum alkaline phosphatase (SAP) 1

Outcome Breakdown

Recovered/Normal

6 (46.2%)

Outcome Unknown

4 (30.8%)

Ongoing

2 (15.4%)

Euthanized

1 (7.7%)

Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.